BD1047 HBr
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522998

CAS#: 138356-21-5

Description: BD1047 is a potent and selective Sigma-1 Receptor Antagonist. It has effects in animal studies suggestive of antipsychotic activity and may also be useful in the treatment of neuropathic pain. BD-1047 has >50-fold selectivity at σ1 over σ2 and also >100-fold selectivity over opiate, phencyclidine, muscarinic, dopamine, α1- & α2-adrenoceptor, 5-HT1, and 5-HT2.


Price and Availability

Size
Price

10mg
USD 120
100mg
USD 650
1g
USD 2650
Size
Price

25mg
USD 190
200mg
USD 950
2g
USD 3850
Size
Price

50mg
USD 350
500mg
USD 1650
5g
Ask price

BD1047 HBr, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 522998
Name: BD1047 HBr
CAS#: 138356-21-5
Chemical Formula: C13H22Br2Cl2N2
Exact Mass:
Molecular Weight: 437.041
Elemental Analysis: C, 35.73; H, 5.07; Br, 36.57; Cl, 16.22; N, 6.41


Synonym: BD-1047; BD 1047; BD1047; BD-1047 HBr.

IUPAC/Chemical Name: N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide

InChi Key: WOALTFHGLDVJHK-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H20Cl2N2.2BrH/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11;;/h4-5,10H,6-9H2,1-3H3;2*1H

SMILES Code: CN(CCN(CCC1=CC=C(Cl)C(Cl)=C1)C)C.[H]Br.[H]Br


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015;2015:265056. doi: 10.1155/2015/265056. Epub 2015 Nov 30. PubMed PMID: 26696751; PubMed Central PMCID: PMC4677253.

2: Jeong YC, Son JS, Kwon YB. The spinal antinociceptive mechanism determined by systemic administration of BD1047 in zymosan-induced hyperalgesia in rats. Brain Res Bull. 2015 Oct;119(Pt A):93-100. doi: 10.1016/j.brainresbull.2015.07.006. Epub 2015 Oct 1. PubMed PMID: 26434709.

3: Yoon SY, Kang SY, Kim HW, Kim HC, Roh DH. Clonidine Reduces Nociceptive Responses in Mouse Orofacial Formalin Model: Potentiation by Sigma-1 Receptor Antagonist BD1047 without Impaired Motor Coordination. Biol Pharm Bull. 2015;38(9):1320-7. doi: 10.1248/bpb.b15-00183. PubMed PMID: 26328487.

4: Su DA, Jiang RY, Liu N, Ding LC, Wang DM, Yu HY, Yan ES, Zhu MH, Zhu B. Effects of BD1047, a σ(1) receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells. Exp Ther Med. 2014 Feb;7(2):435-438. Epub 2013 Dec 5. PubMed PMID: 24396420; PubMed Central PMCID: PMC3881039.

5: Roh DH, Yoon SY. Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model. Biol Pharm Bull. 2014;37(1):145-51. Epub 2013 Oct 24. PubMed PMID: 24152609.

6: Son JS, Kwon YB. Sigma-1 Receptor Antagonist BD1047 Reduces Allodynia and Spinal ERK Phosphorylation Following Chronic Compression of Dorsal Root Ganglion in Rats. Korean J Physiol Pharmacol. 2010 Dec;14(6):359-64. doi: 10.4196/kjpp.2010.14.6.359. Epub 2010 Dec 31. PubMed PMID: 21311675; PubMed Central PMCID: PMC3034114.

7: Fritz M, Klement S, El Rawas R, Saria A, Zernig G. Sigma1 receptor antagonist BD1047 enhances reversal of conditioned place preference from cocaine to social interaction. Pharmacology. 2011;87(1-2):45-8. doi: 10.1159/000322534. Epub 2010 Dec 29. PubMed PMID: 21196793.

8: Kwon YB, Jeong YC, Kwon JK, Son JS, Kim KW. The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats. Korean J Physiol Pharmacol. 2009 Dec;13(6):425-9. doi: 10.4196/kjpp.2009.13.6.425. Epub 2009 Dec 31. PubMed PMID: 20054487; PubMed Central PMCID: PMC2802301.

9: Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology. 2008 Nov;109(5):879-89. doi: 10.1097/ALN.0b013e3181895a83. PubMed PMID: 18946301.

10: McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol. 1999 Apr 16;370(3):225-32. PubMed PMID: 10334496.

11: Zambon AC, De Costa BR, Kanthasamy AG, Nguyen BQ, Matsumoto RR. Subchronic administration of N-[2-(3,4-dichlorophenyl) ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD1047) alters sigma 1 receptor binding. Eur J Pharmacol. 1997 Apr 11;324(1):39-47. PubMed PMID: 9137911.